NEUREN PHARMACEUTICALS LIMITED



GENERAL MEETING Tuesday, 29 August, 2017

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

			Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
Resolution		Votes For	Votes Against	Votes Discretionary	Votes <i>Abstain</i>	For	Against	Abstain **	
1	APPROVAL BE GIVEN TO THE COMPANY TO ISSUE 9,677,419 SHARES TO ESSEX CASTLE LIMITED AT AN ISSUE PRICE OF \$0.062 PER SHARE.	674,776,573	1,877,597	13,761,747	4,500	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands	
2	APPROVAL BE GIVEN TO THE COMPANY TO ISSUE 1,290,323 SHARES TO KAREN ELIZABETH TREAGUS ATF TREAGUS FAMILY TRUST AT AN ISSUE PRICE OF \$0.062 PER SHARE.	713,467,380	3,075,905	13,761,747	0	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands	
3	APPROVAL BE GIVEN TO THE COMPANY TO ISSUE 1,290,323 SHARES TO LARRY GLASS AT AN ISSUE PRICE OF \$0.062 PER SHARE.	764,613,172	2,040,998	13,761,747	4,500	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands	
4	APPROVAL IS GIVEN TO THE PRIOR ISSUE ON 11 AND 12 JULY 2017 OF 11,935,485 SHARES AT AN ISSUE PRICE OF \$0.062 PER SHARE	736,359,583	2,857,597	3,116,585	4,500	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands	
5	APPROVAL IS GIVEN TO THE PRIOR ISSUE TO LANSTEAD CAPITAL L.P. ON 18 JULY 2017 OF 161,290,323 SHARES AT AN ISSUE PRICE OF \$0.062 PER SHARE AND 8,064,516 SHARES AS CONSIDERATION FOR ENTERING A SHARING AGREEMENT.	682,658,471	2,857,597	14,899,849	80,004,500	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands	

^{** -} Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item